

Michael S Anglesio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7965867/publications.pdf>

Version: 2024-02-01

64
papers

6,887
citations

126907

33
h-index

110387

64
g-index

68
all docs

68
docs citations

68
times ranked

9293
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. <i>New England Journal of Medicine</i> , 2010, 363, 1532-1543.	27.0	1,460
2	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. <i>Cancer</i> , 2017, 123, 802-813.	4.1	552
3	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	27.0	451
4	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. <i>Journal of Pathology</i> , 2013, 231, 21-34.	4.5	357
5	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , 2013, 14, 853-862.	10.7	335
6	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , 2018, 173, 1755-1769.e22.	28.9	261
7	Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. <i>Gynecologic Oncology</i> , 2011, 121, 407-415.	1.4	225
8	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017, 49, 856-865.	21.4	220
9	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	7.0	217
10	Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. <i>PLoS ONE</i> , 2013, 8, e72162.	2.5	200
11	Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. <i>PLoS ONE</i> , 2011, 6, e18064.	2.5	172
12	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <i>HER2</i> targeting in 19% of carcinomas. <i>Journal of Pathology</i> , 2013, 229, 111-120.	4.5	169
13	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. <i>Oncotarget</i> , 2015, 6, 37663-37677.	1.8	142
14	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. <i>Journal of Pathology</i> , 2015, 236, 201-209.	4.5	131
15	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv428.	6.3	128
16	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. <i>BMC Cancer</i> , 2015, 15, 415.	2.6	116
17	Subtype-specific mutation of <i>PPP2R1A</i> in endometrial and ovarian carcinomas. <i>Journal of Pathology</i> , 2011, 223, 567-573.	4.5	114
18	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3935.	12.8	110

#	ARTICLE	IF	CITATIONS
19	Oncogenic mutations in histologically normal endometrium: the new normal?. <i>Journal of Pathology</i> , 2019, 249, 173-181.	4.5	106
20	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 2537-2548.	7.0	101
21	Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. <i>Human Molecular Genetics</i> , 2004, 13, 2061-2074.	2.9	100
22	Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver. <i>Clinical Cancer Research</i> , 2014, 20, 6618-6630.	7.0	96
23	Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. <i>Ecancermedalscience</i> , 2018, 12, 803.	1.1	71
24	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1548-1557.	3.7	70
25	The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors. <i>Neoplasia</i> , 2015, 17, 650-660.	5.3	59
26	Endometriosis-associated Ovarian Cancers. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 711-727.	1.1	56
27	Histotype classification of ovarian carcinoma: A comparison of approaches. <i>Gynecologic Oncology</i> , 2018, 151, 53-60.	1.4	54
28	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
29	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. <i>Molecular Cancer Research</i> , 2017, 15, 250-258.	3.4	52
30	Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. <i>Clinical Cancer Research</i> , 2019, 25, 5937-5946.	7.0	50
31	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
32	BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 825-832.	2.5	42
33	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5400-5410.	7.0	41
34	Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. <i>Journal of Pathology</i> , 2015, 237, 215-225.	4.5	38
35	ARID1A Mutations Promote P300-Dependent Endometrial Invasion through Super-Enhancer Hyperacetylation. <i>Cell Reports</i> , 2020, 33, 108366.	6.4	36
36	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	6.4	35

#	ARTICLE	IF	CITATIONS
37	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1187-1193.	2.5	31
38	APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. <i>Gynecologic Oncology</i> , 2017, 147, 663-671.	1.4	29
39	Nuclear β -catenin and <i>CDX2</i> expression in ovarian endometrioid carcinoma identify patients with favourable outcome. <i>Histopathology</i> , 2019, 74, 452-462.	2.9	29
40	Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1495-1503.	4.1	26
41	HACE1 is a potential tumor suppressor in osteosarcoma. <i>Cell Death and Disease</i> , 2019, 10, 21.	6.3	22
42	Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma. <i>PLoS ONE</i> , 2013, 8, e82406.	2.5	22
43	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. <i>Clinical Cancer Research</i> , 2022, 28, 4947-4956.	7.0	22
44	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
45	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3828.	3.7	19
46	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. <i>PLoS ONE</i> , 2016, 11, e0153844.	2.5	17
47	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020, 158, 702-709.	1.4	15
48	Selection of endometrial carcinomas for <i>p53</i> immunohistochemistry based on nuclear features. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 19-32.	3.0	15
49	Validated biomarker assays confirm that <i>ARID1A</i> loss is confounded with <i>MMR</i> deficiency, <i>CD8</i> ⁺ <i>TIL</i> infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	4.5	15
50	You won't believe this old test that does cheap single-cell mutation detection. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 149-153.	3.0	14
51	Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. <i>American Journal of Cancer Research</i> , 2016, 6, 2235-2251.	1.4	14
52	LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. <i>Gynecologic Oncology</i> , 2017, 147, 642-647.	1.4	13
53	Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 324-330.	1.4	13
54	Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on <i>tp53</i> sequencing results: implications for biology, classification, and staging. <i>Modern Pathology</i> , 2018, 31, 652-659.	5.5	12

#	ARTICLE	IF	CITATIONS
55	Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes. <i>Fertility and Sterility</i> , 2022, 118, 524-534.	1.0	12
56	Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation. <i>PLoS ONE</i> , 2017, 12, e0178989.	2.5	11
57	Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 168-179.	1.4	9
58	Pathogenesis of bowel endometriosis. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 71, 2-13.	2.8	8
59	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
60	Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. <i>Histopathology</i> , 2017, 71, 1014-1017.	2.9	6
61	Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping. <i>Reproductive Sciences</i> , 2021, 28, 2743-2757.	2.5	6
62	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 855-862.	2.8	5
63	Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2251-2259.	2.5	2
64	A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5583-5583.	1.6	1